Serum matrix metalloproteinase-9 (MMP9) and amyloid-beta protein precursor (APP) as potential biomarkers in children with Fragile-X syndrome: A cross sectional study.

[1]  F. Corbin,et al.  An “Omic” Overview of Fragile X Syndrome , 2021, Biology.

[2]  D. Bakir,et al.  Evidence supporting the role of telomerase, MMP-9, and SIRT1 in attention-deficit/hyperactivity disorder (ADHD) , 2020, Journal of Neural Transmission.

[3]  R. Hagerman,et al.  Fragile X syndrome: clinical presentation, pathology and treatment. , 2019, Gaceta medica de Mexico.

[4]  Kelli C. Dominick,et al.  Peripheral Amyloid Precursor Protein Derivative Expression in Fragile X Syndrome , 2019, Front. Integr. Neurosci..

[5]  D. Bailey,et al.  Early Identification of Fragile X Syndrome through Expanded Newborn Screening , 2019, Brain sciences.

[6]  A. Lumaka,et al.  Fragile X checklists: A meta‐analysis and development of a simplified universal clinical checklist , 2018, Molecular genetics & genomic medicine.

[7]  Heather Cody Hazlett,et al.  Fragile X syndrome , 2017, Nature Reviews Disease Primers.

[8]  R. Hagerman,et al.  Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families , 2017, Pediatrics.

[9]  W. Brown,et al.  Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment , 2017, Pediatrics.

[10]  M. Castellazzi,et al.  Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology , 2016, Disease markers.

[11]  S. Agarwal,et al.  Fragile X syndrome: Current insight , 2016 .

[12]  B. Ray,et al.  Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue , 2016, Scientific Reports.

[13]  J. Lerch,et al.  Regional brain volumes changes in adult male FMR1-KO mouse on the FVB strain , 2016, Neuroscience.

[14]  E. Klann,et al.  Dysregulation and restoration of translational homeostasis in fragile X syndrome , 2015, Nature Reviews Neuroscience.

[15]  R. D'Hooge,et al.  Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to SynapticDeficits in Fragile X Syndrome , 2015, Neuron.

[16]  L. Abbeduto,et al.  Symptoms of Autism in Males with Fragile X Syndrome: A Comparison to Nonsyndromic ASD Using Current ADI-R Scores , 2015, Journal of autism and developmental disorders.

[17]  R. Kooy,et al.  Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials , 2015, Neuropharmacology.

[18]  C. McDougle,et al.  Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. , 2014, Journal of psychiatric research.

[19]  Christos G. Gkogkas,et al.  Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes , 2014, Cell reports.

[20]  D. Mehaney,et al.  Triple Test Screening for Down Syndrome: An Egyptian-Tailored Study , 2014, PloS one.

[21]  L. Abbeduto,et al.  The fragile X syndrome–autism comorbidity: what do we really know? , 2014, Front. Genet..

[22]  V. Biancalana,et al.  EMQN best practice guidelines for the molecular genetic testing and reporting of fragile X syndrome and other fragile X-associated disorders , 2014, European Journal of Human Genetics.

[23]  P. Hickmott,et al.  Genetic Removal of Matrix Metalloproteinase 9 Rescues the Symptoms of Fragile X Syndrome in a Mouse Model , 2014, The Journal of Neuroscience.

[24]  L. Abbeduto,et al.  Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder. , 2014, Research in developmental disabilities.

[25]  Dalyir I. Pretto,et al.  High MMP‐9 activity levels in fragile X syndrome are lowered by minocycline , 2013, American journal of medical genetics. Part A.

[26]  B. Ray,et al.  Autism as early neurodevelopmental disorder: evidence for an sAPPα-mediated anabolic pathway , 2013, Front. Cell. Neurosci..

[27]  S. Rivera,et al.  A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome , 2013, Journal of developmental and behavioral pediatrics : JDBP.

[28]  G. W. Huntley.  Synaptic circuit remodelling by matrix metalloproteinases in health and disease , 2012, Nature Reviews Neuroscience.

[29]  Jakub Wlodarczyk,et al.  MMP9: a novel function in synaptic plasticity. , 2012, The international journal of biochemistry & cell biology.

[30]  M. Bear,et al.  Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. , 2012, Cold Spring Harbor perspectives in biology.

[31]  S. Elsayed,et al.  Consanguineous matings among Egyptian population , 2011 .

[32]  J. Malter,et al.  Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice , 2011, PloS one.

[33]  B. Ray,et al.  Increased Secreted Amyloid Precursor Protein-α (sAPPα) in Severe Autism: Proposal of a Specific, Anabolic Pathway and Putative Biomarker , 2011, PloS one.

[34]  K. Broadie,et al.  Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase , 2011, Disease Models & Mechanisms.

[35]  David B. Holiday,et al.  Seizures in fragile X syndrome: characteristics and comorbid diagnoses. , 2010, American journal on intellectual and developmental disabilities.

[36]  D. Ethell,et al.  Open-label add-on treatment trial of minocycline in fragile X syndrome , 2010, BMC neurology.

[37]  C. McDougle,et al.  Brief Report: Acamprosate in Fragile X Syndrome , 2010, Journal of autism and developmental disorders.

[38]  E. Sekinger,et al.  A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. , 2010, Clinical chemistry.

[39]  Michelle N. Ngo,et al.  Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model , 2008, Journal of Medical Genetics.

[40]  Murrey G. Olmsted,et al.  Co‐occurring conditions associated with FMR1 gene variations: Findings from a national parent survey , 2008, American journal of medical genetics. Part A.

[41]  J. Malter,et al.  FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein , 2007, PLoS biology.

[42]  D. Bredesen,et al.  Correction for Galvan et al., Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664 , 2006, Proceedings of the National Academy of Sciences.

[43]  R. Friedlander.  Outcomes in Neurodevelopmental and Genetic Disorders , 2005 .

[44]  Maha A. Tawfik,et al.  Frequency of fragile-x in x-linked mental retardation , 2008 .